XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 47.75

Change

0.00 (0.00)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+1.11 (+2.43%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.95 (+1.90%)

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.29 (+2.15%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

-0.09 (-1.23%)

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+5.65 (+2.74%)

USD 45.80B
0ZC:F Zscaler Inc

+0.02 (+0.01%)

USD 37.92B
BSND:F Danone SA

N/A

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

+0.68 (+0.59%)

USD 24.77B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.15% 37% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.15% 37% F 50% F
Trailing 12 Months  
Capital Gain -8.79% 25% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.79% 24% F 44% F
Trailing 5 Years  
Capital Gain 35.19% 48% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.19% 49% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 10.55% 70% C- 66% D+
Dividend Return 10.55% 67% D+ 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.52% 64% D 90% A-
Risk Adjusted Return 100.37% 90% A- 93% A
Market Capitalization 0.85B 71% C- 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike